Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EAN 2026 | Can selected patients with multiple sclerosis safely discontinue ocrelizumab?

Franz Felix Konen • 28 Jul 2026

EAN 2026

Multiple Sclerosis and Related Disorders Antibodies Ocrelizumab

Franz Felix Konen, MD, PhD, Hannover Medical School, Hannover, Germany, presents findings from a study examining ocrelizumab discontinuation in multiple sclerosis. Dr Konen discusses the impact of ocrelizumab discontinuation on survival outcomes, the optimal treatment duration, and the appropriate length of treatment interruption. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.